皮质类固醇对多发性骨髓瘤的联合化疗无效。芬兰白血病研究小组。
Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma. Finnish Leukaemia Group.
作者信息
Palva I P, Ala-Harja K, Almqvist A, Elonen E, Hallman H, Hänninen A, Ilvonen M, Isomaa B, Jouppila J, Järvenpää E
机构信息
Hatanpää Hospital, Tampere, Finland.
出版信息
Eur J Haematol. 1993 Aug;51(2):98-101.
In a randomised multicentre trial a combination of methylprednisolone, vincristine, lomustine, cyclophosphamide and melphalan (MOCCA) was compared with the same regimen omitting methylprednisolone after the first course (COLA) in previously untreated patients with multiple myeloma. The MOCCA arm showed a response rate of 72% among 79 patients and the COLA arm a response rate of 60% among 59 patients. This difference was not statistically significant. The median survival time was 56 months in the MOCCA arm and 61 months in the COLA arm. There was a slight increase of early deaths (within the first 6 months) in the MOCCA arm as compared with the COLA arm. We conclude that, in multidrug therapies, the continuation of corticosteroid at conventional dosage beyond the first course does not improve response rate or survival time in multiple myeloma.
在一项随机多中心试验中，将甲泼尼龙、长春新碱、洛莫司汀、环磷酰胺和美法仑联合方案（MOCCA）与在初治多发性骨髓瘤患者中首个疗程后省略甲泼尼龙的相同方案（COLA）进行了比较。MOCCA组79例患者的缓解率为72%，COLA组59例患者的缓解率为60%。这种差异无统计学意义。MOCCA组的中位生存时间为56个月，COLA组为61个月。与COLA组相比，MOCCA组早期死亡（前6个月内）略有增加。我们得出结论，在多药治疗中，首个疗程后继续使用常规剂量的皮质类固醇并不能提高多发性骨髓瘤的缓解率或生存时间。
Zotero 插件